TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06149351

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Bio-fluid analysis for the implementation of a diagnostic test for sport related concussion
Description: Saliva of participants will be sampled for analysis of biomarkers of interest (nucleic acids and proteins). The nucleic acids biomarkers will be quantified by reverse transcription followed by amplification (RT-PCR) and Next Generation Sequencing (NGS) techniques while enzymatic assay methods (ELISA) methods will be used to quantify protein biomarkers.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Bio-fluid analysis for the implementation of a diagnostic test for sport related concussion
Description: Saliva of participants will be sampled for analysis of biomarkers of interest (nucleic acids and proteins). The nucleic acids biomarkers will be quantified by reverse transcription followed by amplification (RT-PCR) and Next Generation Sequencing (NGS) techniques while enzymatic assay methods (ELISA) methods will be used to quantify protein biomarkers.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Bio-fluid analysis for the implementation of a diagnostic test for sport related concussion
Description: Saliva of participants will be sampled for analysis of biomarkers of interest (nucleic acids and proteins). The nucleic acids biomarkers will be quantified by reverse transcription followed by amplification (RT-PCR) and Next Generation Sequencing (NGS) techniques while enzymatic assay methods (ELISA) methods will be used to quantify protein biomarkers.
Study: NCT05490160

Intervention type: DRUG
Intervention: Tranexamic acid
Description: During the total knee arthroplasty, the patients received a 2-g retrograde injection of tranexamic acid through the drain after closure, with subsequent clamping of the drain for 6 hours.
Study: NCT05653648

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potato starch
Description: Participants will consume 24 grams (days 1-15) and 48 grams (days 16-30) of potato starch. Potato starch is a type 2 resistant starch that is available over the counter.
Study: NCT05086692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDNA11
Description: MDNA11 will be administered, IV on a once every 2 weeks (Q2W) dosing schedule. Provisional dose cohorts for monotherapy dose escalation doses ranging from 0.003 to 0.6 (mg/kg): until determining the monotherapy Recommended Dose for Expansion (mRDE).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®)
Description: MDNA11 will be administered in combination with pembrolizumab, IV. MDNA11 dose range to be evaluated in combination with pembrolizumab until determining the combination Recommended Dose for Expansion (cRDE).
Study: NCT06663176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RESP302
Description: Nitric Oxide agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RESP303
Description: Nitric Oxide agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RESP303
Description: Nitric Oxide agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RESP303
Description: Nitric Oxide agent
Study: NCT06662929

Intervention type: RADIATION
Intervention: Radiation
Description: Radiotherapy for the Head \& Neck Cancer
Study: NCT06662565

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral modification
Description: It includes:~.- Reducing or eliminating smoking and carbonated drinks.~* Weight loss in overweight or obese individuals.~* Caffeine Reduction: Limiting caffeine intake, especially for those consuming at least 400 mg per day.~* Consume Adequate Water: 6 to 8 glasses of water per day.~* Refrain from consuming fluids 2 to 3 hours before bedtime.~* Identify Bladder Irritants: such as sugar substitutes, citrus fruits, and tomato.~* Increasing fiber intake like fruits, and vegetables to reduce constipation with adequate hydration to make stools softer and easier to pass

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral modification
Description: It includes:~.- Reducing or eliminating smoking and carbonated drinks.~* Weight loss in overweight or obese individuals.~* Caffeine Reduction: Limiting caffeine intake, especially for those consuming at least 400 mg per day.~* Consume Adequate Water: 6 to 8 glasses of water per day.~* Refrain from consuming fluids 2 to 3 hours before bedtime.~* Identify Bladder Irritants: such as sugar substitutes, citrus fruits, and tomato.~* Increasing fiber intake like fruits, and vegetables to reduce constipation with adequate hydration to make stools softer and easier to pass

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor down-training
Description: Pelvic floor down training exercises aimed at promoting relaxation and deconditioning of the pelvic floor muscles (PFM). It will be practiced three sessions per week for 8 weeks.~Biofeedback-Assisted pelvic floor down-training:~Procedure:~* Rectal biofeedback will be inserted.~* The therapist asks the woman to focus on consciously relaxing and releasing the PFM after each contraction or exercise while watching biofeedback screen.~* Then, breathe deeply and fully into her abdomen, allowing her pelvic floor to naturally relax and lengthen.~* And to incorporate relaxation techniques such as visualization, or progressive muscle relaxation to promote overall muscle relaxation and reduce PFM tension.~* Exercises are typically repeated around 10-20 times per session. This number can vary depending on the patient's condition and tolerance, as well as the therapist's assessment and treatment plan.
Study: NCT06663566

Intervention type: OTHER
Intervention: Diagnose the patients right heart function as well as right heart fibrosis
Description: Diagnose the patients right heart function as well as right heart fibrosis
Study: NCT06124001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
Description: Intratumoral injection only. Dosing days may be Days 1-2 or Days 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab for Injection
Description: Administered once at 3 mg/kg intravenously on Days 8 of each cycle.
Study: NCT05181176

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffee
Description: 3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea
Description: 3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Herbal tea (placebo)
Description: 3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
Study: NCT06123624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane Inhalation Solution
Description: Keeping the anesthesia using desflurane inhalation solution as 1 minimal alveolar concentration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane Inhalation Solution
Description: Keeping the anesthesia using sevoflurane inhalation solution as 1 minimal alveolar concentration
Study: NCT04716816

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stripping massage
Description: Stripping massage for rhomboid myofascial trigger points
Study: NCT06452862

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Both Diabetics and Healthy Volunteers will undergo MRI protocols including Blood Oxygen Level Dependence (BOLD), Intravoxel Incoherent Motion (IVIM), Arterial Spin Labeling (ASL), T1\&T2-mapping imaging and Magnetic Resonance Elastography (MRE). For Diabetics, blood tests for creatinine and cystatin C, along with blood pressure measurements, will be taken within a three-day window surrounding the MRE test. Additionally, Diabetics will undergo a renal biopsy to assess the extent of kidney damage.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Both Diabetics and Healthy Volunteers will undergo MRI protocols including Blood Oxygen Level Dependence (BOLD), Intravoxel Incoherent Motion (IVIM), Arterial Spin Labeling (ASL), T1\&T2-mapping imaging and Magnetic Resonance Elastography (MRE). For Diabetics, blood tests for creatinine and cystatin C, along with blood pressure measurements, will be taken within a three-day window surrounding the MRE test. Additionally, Diabetics will undergo a renal biopsy to assess the extent of kidney damage.
Study: NCT04911075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 85% TCA Solution
Description: * TCA is an acetic acid analogue solution (CCl3COOH) which is formed from the reaction of acetic acid (CH3COOH) with chlorine (3Cl2).~* High concentrations (85 percent) of this solution can penetrate deeply into the epidermis-dermis layer and cause cells necrosis.~* This solution (1-2 milliliter) will be applied to participants cervical tissue (ectocervix and endocervix) using cotton swab for 1-3 minutes.
Study: NCT05292339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone injection to the shoulder, elbow, wrist, or hand
Description: Triamcinolone is a corticosteroid that decreases the inflammatory process by inhibiting the release of arachidonic acid from phospholipids.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac injection to the shoulder, elbow, wrist, or hand
Description: Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that reduces inflammation by inhibiting Cyclo-oxygenase (COX)-2 dependent prostaglandin release via the cyclooxygenase pathway.
Study: NCT06663566

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnose the patient&#39;s right heart function as well as right heart fibrosis
Description: Diagnose the patient\&#39;s right heart function as well as right heart fibrosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnose the patient&#39;s right heart function as well as right heart fibrosis
Description: Diagnose the patient\&#39;s right heart function as well as right heart fibrosis
Study: NCT05941845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2A 180 MCG/ML Injectable Solution
Description: Injections will be carried out on the Nephrology day hospitalization ward. The injections follows a personalized administration schedule: all enrolled patients will receive an injection of Pegasys® at Week 0.~Patients with a persistent Th17 profile (cytokine profile showing IL-17A levels greater than 73 pg/ml) at Week 2 will receive a new dose of Pegasys®, followed by a monthly cytokine profile. In the case of a persistent Th17 profile, 2 injections will be given two weeks apart.~In patients with no Th17 profile at Week 2, no Pegasys® injections will be performed at this time. Cytokine profiles will be performed monthly, and in the case of a persistent Th17 profile, 1 injection will be performed.~In total, patients will receive a minimum of one injection and a maximum of 13 injections of 180 µg (1 injection every two weeks for 24 weeks).
Study: NCT05990946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ePRO based Remote Symptom Management provide by a mobile phone app
Description: Alerts are triggered if any of 5 core symptoms scored ≥4, prompting remote clinician feedback and guidance on symptom management. This is facilitated through the Shuyu mobile application, which serves as the platform for monitoring symptoms and communication.
Study: NCT04552158

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: The Mediterranean diet (MedDiet) is a nutritional model inspired by the traditional dietary pattern of some of the countries of the Mediterranean basin. Mediterranean dietary pattern (MDP) gather the following characteristics: abundant consumption of olive oil and high consumption of fruits, vegetables, cereals (preferably as whole grain), legumes, nuts and seeds. The MDP also includes moderate consumption of fish and shellfish, white meat, eggs, and fermented dairy products (cheese and yogurt), as well as relatively small amounts of red meat, processed meats, and foods rich in sugars. Frequent but moderate intake of wine, especially red wine with meals is also recommended
Study: NCT06664242

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: these patients will be subjected to the same usual routine of pharmacological analgesia, consisting of the administration of 1g of dipyrone at the discretion, with escalation to tramal (dose) and physiotherapy in the hospital ICU, in addition to an application of TENS, with the device turned on, with programming on channels that are not connected to the patients, so as to generate visual and auditory feedback.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS low frequence group
Description: Patients in this group will undergo the hospital usual analgesia and physiotherapy routine, in addition to conventional TENS with a low frequency of 5 Hz and a pulse width of 250 µs.
Study: NCT06537479

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Buteyko breathing technique
Description: Participants will be advised to sit in a comfortable and relaxed position and take a shallow breath through nose, partially filling the lungs. Hold breath for 2-3 seconds and exhale slowly through the nose and emptying the lungs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buteyko breathing technique
Description: Participants will be advised to sit in a comfortable and relaxed position and take a shallow breath through nose, partially filling the lungs. Hold breath for 2-3 seconds and exhale slowly through the nose and emptying the lungs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest Wall Mobilization
Description: It started with positioning, sitting or standing with good posture, and relaxing shoulders and arms. Hands were placed on the chest with fingers wide and thumbs on side of ribcage. Inhale deep breaths with expansion of chest and hands move outward. Exhale slowly allowed the chest to drop and the hands to move inward.
Study: NCT06664242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional TENS
Description: In this group, patients will undergo the usual routine of analgesia and hospital physiotherapy, in addition to TENS with a frequency of 140 Hz, pulse width of 50 µs.
Study: NCT00811031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: 75 mg/m\^2 Day 1 of every 21-day cycle by vein for 4 cycles prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg twice a day by mouth.
Study: NCT06170632

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary drainage
Description: Biliary drainage with FC-SEMS Niti-S FLARE TYPE

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary drainage
Description: Biliary drainage with FC-SEMS Niti-S FLARE TYPE
Study: NCT06017856

Intervention type: OTHER
Intervention: Life style intervention program
Description: Life style intervention program for the obese/overweight subjects conducted regardless of this study at the child sport and health center at Meir medical center
Study: NCT06023511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation
Description: While study subjects are connected to standard ICU monitors, electrical muscle stimulation will be applied at the level of the quadriceps muscle to induce palpable or visible muscle contraction. (No control group or sham procedure in this study).
Study: NCT06663787

Intervention type: DRUG
Intervention: Trastuzumab (Herceptin)
Description: Continuing anti-HER2 treatment

Intervention type: DIAGNOSTIC_TEST
Intervention: SIgnatera
Description: A personalized, tumor-informed test.

Intervention type: DIAGNOSTIC_TEST
Intervention: SIgnatera
Description: A personalized, tumor-informed test.
Study: NCT06663605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PALI-2108
Description: Oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PALI-2108 Placebo
Description: Oral dose
Study: NCT05869227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine/Placebo combined with toripalimab
Description: Combined

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine/Placebo combined with toripalimab
Description: Combined
Study: NCT06615570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-973
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-973
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension for oral administration.
Study: NCT06230367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual health advocacy for guys
Description: 5 month HIV prevention program delivered via text messaging

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy lifestyle control
Description: 5 month control group program delivered via text messaging
Study: NCT06052904

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth-delivered music breathing therapy
Description: Parental caregivers in the intervention group will receive individual home-based music breathing therapy comprising eight 1-hour weekly sessions for 2 months delivered through Zoom, by a qualified music therapist based on a standardized and validated music breathing instruction manual. The music breathing therapy comprises four breathing phases, namely Discovery Breathing, Triangular Breathing, Silent Breathing, and Music Breathing. In each session, participants will practice breathing for approximately 20-25 minutes in silence or with music in a sitting position. Thereafter, the participants will be instructed to create a Mandala drawing to visualize the effects of breathing on their mental body image, emotions, and thoughts. Each session will end with a debriefing session, which will serve to verbally integrate and reflect the participants' experiences and mental states.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online educational modules
Description: Participants in the control group will receive eight weekly online educational modules via email for 2 months. The content of the online educational modules will include medical information and advice about caring for a child who has been newly diagnosed with cancer.
Study: NCT05927012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KER-047
Description: Oral tablet, daily (or every other day) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KER-047
Description: Oral tablet, daily (or every other day) administration
Study: NCT05583461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure titration
Description: Positive end-expiratory pressure level

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure titration
Description: Positive end-expiratory pressure level

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure titration
Description: Positive end-expiratory pressure level

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure titration
Description: Positive end-expiratory pressure level
Study: NCT06461806

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplement - Plant protein
Description: Pea/lupine protein powder mix

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplement - Animal protein
Description: Whey protein powder
Study: NCT05348083

Intervention type: PROCEDURE
Intervention: ESPB
Description: Echo-guided bilateral ESPB performed at T9 level at the end of surgery with a mixture of ropivacaine 0.375% and epinephrine 5 mcg/mL 20 mL each side.
Study: NCT05378269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen vaginal insert
Study: NCT04843046

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be filled with corn starch and riboflavin.
Study: NCT05378269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen vaginal insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen vaginal insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen vaginal insert

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaginal insert
Study: NCT06380101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEAAR Medical Food
Description: Standardized non-essential amino acid restricted medical food.
Study: NCT04698252

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation therapy for oligometastatic sites

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery for oligometastatic sites

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation for oligometastatic sites
Study: NCT06146387

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Investigational Formula
Description: Participants in this arm will receive stage 1 and stage 2 investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Formula
Description: Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Breastfeeding
Description: Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
Study: NCT04962958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
Study: NCT05586399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maximal strength training in COPD
Description: Participate in a rehabilitation program for 4 weeks, with exercise 5 times a week. Supervised maximal strength training in a leg press machine for a total of 20 exercise sessions. Patients will participate in rehabilitation in one of two rehabilitations centers in Trondheim, Norway.
Study: NCT04962958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfox Protocol
Description: Oxaliplatin , fluorouracil, and leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: administration of Donafenib